Atea Pharmaceuticals (AVIR) Profit After Tax (2019 - 2026)

Atea Pharmaceuticals' Profit After Tax history runs 8 years deep, the most recent figure standing at -$45.7 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 32.93% year-over-year to -$45.7 million in Q1 2026; TTM through Mar 2026 was -$169.7 million, a 21.55% decrease from a year earlier, with the FY2025 full-year figure at -$158.4 million, up 5.91% from the prior year.
• Profit After Tax fell to -$45.7 million in Q1 2026 per AVIR's latest filing, from -$44.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$8.1 million in Q3 2022 and bottomed at -$63.2 million in Q1 2024.
• The 5-year median for Profit After Tax is -$35.5 million (2023), against an average of -$36.7 million.
• Biggest YoY gain for Profit After Tax was 71.39% in 2022; the steepest drop was 2136.06% in 2022.
• Year by year, Profit After Tax stood at -$34.3 million in 2022, then slipped by 11.71% to -$38.3 million in 2023, then increased by 12.43% to -$33.5 million in 2024, then slumped by 34.05% to -$44.9 million in 2025, then decreased by 1.74% to -$45.7 million in 2026.
• Per Business Quant, the three latest AVIR Profit After Tax figures stand at -$45.7 million (Q1 2026), -$44.9 million (Q4 2025), and -$41.8 million (Q3 2025).